Drugs / ABBV-319
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06977724 | Aug 2025 → Mar 2029 expected | dry eye syndrome, systemic lupus erythematosus | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT05512390 | Apr 2023 → Feb 2027 expected | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-319 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05512390 ↗ |
| Action | Deplete | “ABBV-319 exhibits potential B cell depletion in SLE and SjD” NCT06977724 ↗ |
| Route | Intravenous | “Intravenous (IV); Infusion” NCT05512390 ↗ |